Equillium Inc
NASDAQ:EQ
Equillium Inc
Accounts Payable
Equillium Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Accounts Payable
$3.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$833m
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$21.5B
|
CAGR 3-Years
150%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.6B
|
CAGR 3-Years
165%
|
CAGR 5-Years
110%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$5.7B
|
CAGR 3-Years
116%
|
CAGR 5-Years
68%
|
CAGR 10-Years
50%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Accounts Payable?
Accounts Payable
3.7m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Accounts Payable amounts to 3.7m USD.
What is Equillium Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
6%
Over the last year, the Accounts Payable growth was 2%. The average annual Accounts Payable growth rates for Equillium Inc have been 11% over the past three years , 6% over the past five years .
You don't have any saved screeners yet